Grantham, Mayo, Van Otterloo & Co (GMO)’s Amedisys AMED Stock Holding History

Grantham, Mayo, Van Otterloo & Co (GMO)’s Portfolio AMED Stock Details AMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-164,064	Closed	-$15.2M	–	611
2025 Q1	$15.2M	Buy	+164,064	New	+$15.1M	0.05%	204
2024 Q4	–	Sell	-141,521	Closed	-$13.7M	–	573
2024 Q3	$13.7M	Buy	+141,521	New	+$13.8M	0.04%	237
2023 Q4	–	Sell	-314,914	Closed	-$29.4M	–	490
2023 Q3	$29.4M	Buy	314,914 +215,233	+216%	+$19.9M	0.14%	136
2023 Q2	$9.11M	Buy	+99,681	New	+$8.18M	0.04%	267
2020 Q2	–	Sell	-7,300	Closed	-$1.34M	–	746
2020 Q1	$1.34M	Buy	+7,300	New	+$1.3M	0.01%	460

Other funds holding AMED

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TAL

TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO)'s AMED Position: Q2 2025 in Review

Grantham, Mayo, Van Otterloo & Co (GMO) sold out of Amedisys (AMED) in Q2 2025, closing a stake of 164,064 shares — an estimated $15.2M sold.

Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in AMED in Q1 2020 and held it in 5 quarters. The position peaked at $29.4M in Q3 2023. 319 funds tracked by Wall St. Rank hold AMED as of Q2 2025.

Grantham, Mayo, Van Otterloo & Co (GMO) reported no remaining Amedisys position as of Q2 2025 after selling out during the quarter.
Grantham, Mayo, Van Otterloo & Co (GMO) sold 164,064 Amedisys shares in Q2 2025, an estimated $15.2M.
Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in Amedisys in Q1 2020 and held it in 5 quarters.
Grantham, Mayo, Van Otterloo & Co (GMO)'s Amedisys position peaked at $29.4M in Q3 2023.
319 funds tracked by Wall St. Rank held Amedisys as of Q2 2025.

Based on Grantham, Mayo, Van Otterloo & Co (GMO)'s 13F filing for Q2 2025, filed 13 Aug 2025.